BRG has successfully completed an FDA inspection with a positive outcome. This result not only validates the effectiveness of our internal processes but also demonstrates our unwavering commitment to the highest standards of quality and compliance. It reinforces the trust in the systems we have built to support both our operations and those of our partners and clients.
FDA inspections are a cornerstone of regulatory oversight in clinical research, pharmaceuticals, medical devices, and food industries. Their purpose is to ensure that organizations operate safely, transparently, and in compliance with regulations to protect public health. A positive outcome is a strong signal to sponsors, partners, and stakeholders that BRG operates in line with global best practices.
Benefits for Our Partners
-
Risk reduction – our expertise minimizes the likelihood of financial or reputational risks that can arise from compliance gaps.
-
Responsiveness – we help organizations establish clear procedures and documentation practices, enabling swift and accurate responses to FDA requirements.
-
Long-term quality – our approach goes beyond passing a single inspection. We embed compliance into organizational culture, strengthen processes, and provide a foundation for sustainable operational safety.
The Strength of the BRG Team
This achievement was made possible by the professionalism and dedication of our team. Special recognition goes to Dr. Katarzyna Jarus-Dziedzic, our Principal Investigator, whose extensive clinical expertise and leadership have been instrumental in shaping BRG’s reputation for reliable, high-quality research.
Our Mission
At BRG, regulatory compliance is more than a requirement—it is the foundation for innovative Phase 1 clinical research. Our mission is to support partners in developing future therapies through rigor, transparency, and internationally recognized quality.
The positive FDA inspection is not only a validation of our standards but also an invitation to further growth and collaboration. BRG remains dedicated to excellence, innovation, and trusted partnerships in early-phase clinical research.